Incidence and nature of infectious disease in patients treated with anti-TNF agents

Siba P Raychaudhuri, Caroline T. Nguyen, Smriti K. Raychaudhuri, M. Eric Gershwin

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.

Original languageEnglish (US)
Pages (from-to)67-81
Number of pages15
JournalAutoimmunity Reviews
Volume9
Issue number2
DOIs
StatePublished - Dec 2009

Fingerprint

Communicable Diseases
Tumor Necrosis Factor-alpha
Incidence
Infection
Biological Factors
Physiologic Monitoring
Immunosuppressive Agents
Signs and Symptoms
Clinical Trials
Cytokines
Therapeutics

Keywords

  • Opportunistic infection
  • Rheumatic diseases
  • TNF
  • TNF-α inhibitors
  • Tuberculosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Incidence and nature of infectious disease in patients treated with anti-TNF agents. / Raychaudhuri, Siba P; Nguyen, Caroline T.; Raychaudhuri, Smriti K.; Gershwin, M. Eric.

In: Autoimmunity Reviews, Vol. 9, No. 2, 12.2009, p. 67-81.

Research output: Contribution to journalArticle

@article{87e02ac6d1cb4a15a6c336f7ab5688f4,
title = "Incidence and nature of infectious disease in patients treated with anti-TNF agents",
abstract = "Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.",
keywords = "Opportunistic infection, Rheumatic diseases, TNF, TNF-α inhibitors, Tuberculosis",
author = "Raychaudhuri, {Siba P} and Nguyen, {Caroline T.} and Raychaudhuri, {Smriti K.} and Gershwin, {M. Eric}",
year = "2009",
month = "12",
doi = "10.1016/j.autrev.2009.08.006",
language = "English (US)",
volume = "9",
pages = "67--81",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Incidence and nature of infectious disease in patients treated with anti-TNF agents

AU - Raychaudhuri, Siba P

AU - Nguyen, Caroline T.

AU - Raychaudhuri, Smriti K.

AU - Gershwin, M. Eric

PY - 2009/12

Y1 - 2009/12

N2 - Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.

AB - Tumor necrosis factor α (TNF-α) inhibitors offer a targeted therapeutic strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. These biologic agents have had a significant impact in ameliorating the signs and symptoms of inflammatory rheumatoid disease and improving patient function. From the onset of clinical trials, a central concern of cytokine blockade has been a potential increase in susceptibility to infections. Not surprisingly, a variety of infections have been reported in association with the use of TNF-α inhibitor agents. In particular, there is evidence suggesting an increased rate of granulomatous infections in patients treated with monoclonal TNF-α inhibitors. This review provides the incidence and nature of infections in patients treated with TNF-α inhibitor agents and reminds the clinician of the required vigilance in monitoring patients.

KW - Opportunistic infection

KW - Rheumatic diseases

KW - TNF

KW - TNF-α inhibitors

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=70350566088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350566088&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2009.08.006

DO - 10.1016/j.autrev.2009.08.006

M3 - Article

C2 - 19716440

AN - SCOPUS:70350566088

VL - 9

SP - 67

EP - 81

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 2

ER -